IDEAYA Biosciences
IDYA
25.56
-0.61
-2.33%
IDEAYA Biosciences
US · IDYA
#2357 by market cap
Listed 2019
25.56
-0.61
-2.33%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.7 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 107.09% -0.74pp
- Institutions
- 351 +1
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund78.72%
Hedge Fund19.60%
Public Company4.20%
VC/PE Fund2.41%
Government Pension Fund0.88%
Individual/Insider0.88%
Insurance Company0.55%
Private Company0.39%
Endowment Fund0.23%
Top holders as of 2026-09-30
FMR
14.96% · 14.47M sh
BlackRock
9.87% · 9.55M sh
Janus Henderson Group plc
8.87% · 8.58M sh
Capital Research
5.52% · 5.34M sh
Baker Bros. Advisors LP
5.18% · 5.01M sh
Vanguard Capital Management, LLC
4.46% · 4.31M sh
State Street Global Advisors
4.06% · 3.93M sh
Logos Global Management, L.P.
3.10% · 3.00M sh
Adage Capital Management, L.P.
2.81% · 2.72M sh
Deerfield Management Company, L.P.
2.81% · 2.71M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 42 buys · 6 sells
| Name | Role | Stake |
|---|---|---|
| Yujiro Hata | Chairperson & CEO | 0.71% |
| Jason Throne | Former Chief Legal Officer & Company Secretary | 0.07% |
| Jeffrey Stein | Independent Director | 0.06% |
| Andres Briseno | Chief Accounting Officer | 0.03% |
| Terry Rosen | Lead Independent Director | 0.01% |
| Douglas Snyder | Chief Legal Officer | 0.00% |
| Wendy Yarno | Independent Director | -- |
| Scott William Morrison | Independent Director | -- |
| Catherine Mackey | Independent Director | -- |
| Darrin Beaupre | Chief Medical Officer | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-05 | Yujiro Hata | Chairperson & CEO | Derivative Exercise and Sale | -26,338 | $4.31–38.26 |
| 2026-07-06 | Andres Briseno | Chief Accounting Officer | Derivative Exercise and Sale | -9,550 | $12.86–40.01 |
| 2026-06-15 | Wendy Yarno | Independent Director | Other Derivative Acquisition | +20,000 | $30.57 |
| 2026-06-15 | Jeffrey Stein | Independent Director | Other Derivative Acquisition | +20,000 | $30.57 |
| 2026-06-15 | Scott William Morrison | Independent Director | Other Derivative Acquisition | +20,000 | $30.57 |
| 2026-06-15 | Catherine Mackey | Independent Director | Other Derivative Acquisition | +20,000 | $30.57 |
| 2026-06-15 | Terry Rosen | Lead Independent Director | Other Derivative Acquisition | +20,000 | $30.57 |
| 2026-06-15 | Malcolm Hampton | Independent Director | Other Derivative Acquisition | +20,000 | $30.57 |
| 2026-03-01 | Jeffrey Stein | Independent Director | Open Market Acquisition | +50,000 | $32.96 |
| 2026-01-29 | Yujiro Hata | Chairperson & CEO | Other Derivative Acquisition | +600,000 | $32.19 |
| 2026-01-29 | Douglas Snyder | Chief Legal Officer | Other Derivative Acquisition | +130,000 | $32.19 |
| 2026-01-29 | Darrin Beaupre | Chief Medical Officer | Other Derivative Acquisition | +175,000 | $32.19 |
| 2026-01-29 | Andres Briseno | Chief Accounting Officer | Other Derivative Acquisition | +80,000 | $32.19 |
| 2026-01-29 | Michael White | President of Research & Development | Other Derivative Acquisition | +190,000 | $32.19 |
| 2026-01-29 | Stuart Dorman | Chief Commercial Officer | Other Derivative Acquisition | +155,000 | $32.19 |
| 2026-01-29 | Joshua Bleharski | Chief Financial Officer | Other Derivative Acquisition | +170,000 | $32.19 |
| 2025-11-27 | Douglas Snyder | Chief Legal Officer | Other Acquisition | +2,080 | $16.91 |
| 2025-11-27 | Andres Briseno | Chief Accounting Officer | Other Acquisition | +1,935 | $16.91–23.26 |
| 2025-06-26 | Joshua Bleharski | Chief Financial Officer | Initial Statement of Beneficial | 0 | -- |
| 2025-06-23 | Wendy Yarno | Independent Director | Other Derivative Acquisition | +20,000 | $21.78 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
IDEAYA Biosciences discussion 0 comments